As we age, our innate and adaptive immune system undergoes various changes, typically characterized by decreased lymphopoiesis and adaptive immunity, and increased inflammation and myeloid pathologies. Immunosenescence (the gradual deterioration of the immune system associated with ageing), makes individuals more susceptible to infections, less responsive to vaccines, and prone to the development of chronic inflammatory conditions and autoimmune diseases. Additionally, age-related alterations in the composition and function of the microbiota, the community of microorganisms living in and on the body, can further influence immune function and contribute to the overall ageing process.
This month, several papers related to antibodies and aging were published, including a comprehensive review by Quiros-Roldan et al., studying the impact of immune system aging on infectious diseases, including the progressive reduction of the body’s ability to trigger effective antibody responses. Here they describe the increased public interest in immune system aging due to prolonged life expectancy, contrasted to health expectancy. They also provide an analysis of the immune players involved, in addition to immune cells/mediators within endogenous and exogenous factors and co-morbidities.
Another paper this month provides insight into why age is a major risk factor for severe COVID-19. By evaluating the impact of aging and anti-IFN autoantibodies on host immune response in the blood, upper airway, and nasal microbiome, the researchers found that older age correlated with impaired viral clearance, dysregulated immune signaling, and persistent and potentially pathologic activation of pro-inflammatory genes and proteins.
Ending on a bright note, Ross et al.’s study in Nature demonstrates the antibody-mediated depletion of my-haematopoietic stem cells (HSCs) in aged mice restores characteristic features of a more youthful immune system. Their findings show it might be possible to reverse the ageing phenotype by eliminating my-HSCs in aged mice and contributes to the understanding and intervention of diseases exacerbated or caused by dominance of the haematopoietic system by my-HSCs.
Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events a……
Bispecific antibody-drug conjugates, or BsADCs, combines the payload-delivery fu……
Programmable antibodies can describe several related approaches that make antibo……
Chemical conjugation is the process of using defined chemical reactions to attac……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



